{
  "trials": [
    {
      "id": "CT-2024-001",
      "title": "Phase III Study of Cardiovascular Drug ABC123",
      "sponsor": "PharmaCorp Inc.",
      "drug": "ABC123",
      "indication": "Hypertension",
      "phase": "Phase III",
      "status": "Active",
      "startDate": "2024-01-15",
      "endDate": "2026-01-15",
      "enrollmentTarget": 500,
      "enrollmentCurrent": 342,
      "sites": ["Mayo Clinic", "Johns Hopkins", "Cleveland Clinic"],
      "primaryOutcome": "Reduction in systolic blood pressure",
      "adverseEvents": 12,
      "studyType": "Randomized Controlled Trial"
    },
    {
      "id": "CT-2024-002",
      "title": "Phase II Trial for Diabetes Treatment XYZ789",
      "sponsor": "MedResearch Labs",
      "drug": "XYZ789",
      "indication": "Type 2 Diabetes",
      "phase": "Phase II",
      "status": "Active",
      "startDate": "2024-03-20",
      "endDate": "2025-09-20",
      "enrollmentTarget": 200,
      "enrollmentCurrent": 187,
      "sites": ["Stanford Medical", "Mass General", "UCLA Medical"],
      "primaryOutcome": "HbA1c reduction",
      "adverseEvents": 5,
      "studyType": "Double-Blind Placebo Controlled"
    },
    {
      "id": "CT-2023-045",
      "title": "Oncology Drug LMN456 in Advanced Lung Cancer",
      "sponsor": "BioTech Innovations",
      "drug": "LMN456",
      "indication": "Non-Small Cell Lung Cancer",
      "phase": "Phase II",
      "status": "Completed",
      "startDate": "2023-05-10",
      "endDate": "2024-11-10",
      "enrollmentTarget": 150,
      "enrollmentCurrent": 150,
      "sites": ["MD Anderson", "Memorial Sloan Kettering", "Dana-Farber"],
      "primaryOutcome": "Overall survival rate",
      "adverseEvents": 28,
      "studyType": "Open Label"
    },
    {
      "id": "CT-2024-003",
      "title": "Alzheimer's Disease Treatment with DEF321",
      "sponsor": "NeuroPharm Solutions",
      "drug": "DEF321",
      "indication": "Alzheimer's Disease",
      "phase": "Phase III",
      "status": "Recruiting",
      "startDate": "2024-02-01",
      "endDate": "2027-02-01",
      "enrollmentTarget": 800,
      "enrollmentCurrent": 234,
      "sites": ["Mayo Clinic", "UCSF Medical", "Mount Sinai", "Brigham and Women's"],
      "primaryOutcome": "Cognitive function improvement",
      "adverseEvents": 8,
      "studyType": "Randomized Controlled Trial"
    },
    {
      "id": "CT-2023-089",
      "title": "Antibiotic RST654 for Resistant Bacterial Infections",
      "sponsor": "Global Pharma Research",
      "drug": "RST654",
      "indication": "Multi-Drug Resistant Infections",
      "phase": "Phase I",
      "status": "Completed",
      "startDate": "2023-08-15",
      "endDate": "2024-08-15",
      "enrollmentTarget": 50,
      "enrollmentCurrent": 50,
      "sites": ["NIH Clinical Center"],
      "primaryOutcome": "Safety and tolerability",
      "adverseEvents": 3,
      "studyType": "Dose Escalation"
    },
    {
      "id": "CT-2024-004",
      "title": "Rheumatoid Arthritis Treatment GHI987",
      "sponsor": "ImmunoTherapeutics",
      "drug": "GHI987",
      "indication": "Rheumatoid Arthritis",
      "phase": "Phase III",
      "status": "Active",
      "startDate": "2024-04-01",
      "endDate": "2026-04-01",
      "enrollmentTarget": 600,
      "enrollmentCurrent": 421,
      "sites": ["Hospital for Special Surgery", "Cleveland Clinic", "Mayo Clinic"],
      "primaryOutcome": "ACR20 response rate",
      "adverseEvents": 15,
      "studyType": "Randomized Controlled Trial"
    },
    {
      "id": "CT-2023-112",
      "title": "Depression Treatment QWE159",
      "sponsor": "MindHealth Pharma",
      "drug": "QWE159",
      "indication": "Major Depressive Disorder",
      "phase": "Phase II",
      "status": "Suspended",
      "startDate": "2023-11-01",
      "endDate": "2025-11-01",
      "enrollmentTarget": 300,
      "enrollmentCurrent": 156,
      "sites": ["Johns Hopkins Psychiatry", "McLean Hospital"],
      "primaryOutcome": "MADRS score reduction",
      "adverseEvents": 22,
      "studyType": "Double-Blind Placebo Controlled"
    },
    {
      "id": "CT-2024-005",
      "title": "COVID-19 Antiviral VBN753",
      "sponsor": "Viral Defense Corp",
      "drug": "VBN753",
      "indication": "COVID-19",
      "phase": "Phase III",
      "status": "Active",
      "startDate": "2024-01-10",
      "endDate": "2025-01-10",
      "enrollmentTarget": 1000,
      "enrollmentCurrent": 867,
      "sites": ["Multiple international sites"],
      "primaryOutcome": "Time to viral clearance",
      "adverseEvents": 34,
      "studyType": "Randomized Controlled Trial"
    }
  ]
}
